Skip to main content
Log in

Therapiealternativen zur chirurgischen Versorgung maligner Lidtumoren und deren Vorläuferstufen

Therapeutic alternatives to surgical treatment of malignant eyelid tumors and their precursors

  • Das diagnostische und therapeutische Prinzip
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Therapie der Wahl maligner Lidtumoren ist die chirurgische Exzision. Falls dies nicht möglich oder gewünscht ist, steht eine Reihe alternativer Therapien zur Verfügung. Als systemische Präparate kommen für Basalzellkarzinome Vismodegib und Sonidegib, für Plattenepithelkarzinome Cetuximab und Cemiplimab infrage. Bei oberflächlichen Tumoren ist eine Kryodestruktion möglich. In-situ-Befunde können mit den lokalen Präparaten Imiquimod oder 5‑Fluoruracil sowie mit der photodynamischen Therapie behandelt werden. Die interdisziplinäre Zusammenarbeit mit Kollegen der Dermatologie ist empfehlenswert.

Abstract

The treatment of choice for malignant eyelid tumors is surgical excision. If this is not feasible or undesirable, a number of alternative treatments are available. Possible systemic preparations are vismodegib and sonidegib for basal cell carcinoma as well as cetuximab and cemiplimab for squamous cell carcinoma. Cryodestruction is possible for superficial tumors. In situ findings can be treated with the local preparations imiquimod or 5‑fluorouracil and with photodynamic therapy. An interdisciplinary cooperation with dermatologists is advisable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Anders M, Sporl E, Krantz H, Matthaus W, Seiler T (1995) Cryotherapy of malignant eyelid tumors. Ophthalmologe 92(6):787–792

    CAS  PubMed  Google Scholar 

  2. Avril M, Auperin A, Margulis A, Gerbaulet A, Duvillard P, Benhamou E, Guillaume J, Chalon R, Petit J, Sancho-Garnier H, Prade M, Bouzy J, Chassagne D (1997) Basal cell carcinoma of the face: surgery or radiotherapy? results of a randomized study. Br J Cancer 76(1):100–106. https://doi.org/10.1038/bjc.1997.343

    Article  CAS  PubMed  Google Scholar 

  3. Buschmann W (2002) A reappraisal of cryosurgery for eyelid basal cell carcinomas. Br J Ophthalmol 86(4):453–457

    Article  CAS  Google Scholar 

  4. Cannon PS, O’Donnell B, Huilgol SC, Selva D (2011) The ophthalmic side-effects of imiquimod therapy in the management of periocular skin lesions. Br J Ophthalmol 95(12):1682–1685. https://doi.org/10.1136/bjo.2009.178202

    Article  PubMed  Google Scholar 

  5. Cox KF, Margo CE (2016) Role of vismodegib in the management of advanced periocular basal cell carcinoma. Cancer Control 23(2):133–139. https://doi.org/10.1177/107327481602300207

    Article  PubMed  Google Scholar 

  6. Crowe DL, Hacia JG, Hsieh CL, Sinha UK, Rice H (2002) Molecular pathology of head and neck cancer. Histol Histopathol 17(3):909–914. https://doi.org/10.14670/HH-17.909

    Article  CAS  PubMed  Google Scholar 

  7. Daicker B, Buchner S, Kraus M (1994) Conjunctivalization of Meibomian glands following cryosurgery for basal cell carcinoma of the eyelid. Eur J Ophthalmol 4(1):59–61

    Article  CAS  Google Scholar 

  8. Durkin SR, Roos D, Higgs B, Casson RJ, Selva D (2007) Ophthalmic and adnexal complications of radiotherapy. Acta Ophthalmol Scand 85(3):240–250. https://doi.org/10.1111/j.1600-0420.2006.00822.x

    Article  PubMed  Google Scholar 

  9. Fitzpatrick PJ, Thompson GA, Easterbrook WM, Gallie BL, Payne DG (1984) Basal and squamous cell carcinoma of the eyelids and their treatment by radiotherapy. Int J Radiat Oncol Biol Phys 10(4):449–454. https://doi.org/10.1016/0360-3016(84)90023-3

    Article  CAS  PubMed  Google Scholar 

  10. Gastaud L, Rossignol B, Peyrade F, Re D, Thariat J, Thyss A, Doyen J (2016) Role of radiotherapy in the management of non-Hodgkin lymphomas. Cancer Radiother 20(3):236–247. https://doi.org/10.1016/j.canrad.2016.01.011

    Article  CAS  PubMed  Google Scholar 

  11. Kaufmann R (1997) Chemotherapie des Basalioms. In: Garbe C, Dummer R, Kaufmann R, Tilgen W (Hrsg) Dermatologische Onkologie. Springer, Berlin Heidelberg, S 166–172

    Chapter  Google Scholar 

  12. Ko D‑Y, Jeon S‑Y, Kim K‑H, Song K‑H (2014) Fractional erbium: YAG laser-assisted photodynamic therapy for facial actinic keratoses: a randomized, comparative, prospective study. J Eur Acad Dermatol Venereol 28(11):1529–1539. https://doi.org/10.1111/jdv.12334

    Article  CAS  PubMed  Google Scholar 

  13. Kwa RE, Campana K, Moy RL (1992) Biology of cutaneous squamous cell carcinoma. J Am Acad Dermatol 26(1):1–26. https://doi.org/10.1016/0190-9622(92)70001-v

    Article  CAS  PubMed  Google Scholar 

  14. Limawararut V, Leibovitch I, Sullivan T, Selva D (2007) Periocular squamous cell carcinoma. Clin Experiment Ophthalmol 35(2):174–185. https://doi.org/10.1111/j.1442-9071.2006.01411.x

    Article  PubMed  Google Scholar 

  15. Luxenberg MN, Guthrie TH (1986) Chemotherapy of basal cell and squamous cell carcinoma of the eyelids and periorbital tissues. Ophthalmology 93(4):33708–33704. https://doi.org/10.1016/s0161-6420

    Article  Google Scholar 

  16. Mandel VD, Ferrari F, Ciardo S, Giusti F, Pellacani G (2017) Bowen’s disease of the upper eyelid successfully treated with photodynamic therapy. J Eur Acad Dermatol Venereol 31(2):e127–e129. https://doi.org/10.1111/jdv.13875

    Article  CAS  PubMed  Google Scholar 

  17. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD et al (2018) PD‑1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 379(4):341–351. https://doi.org/10.1056/NEJMoa1805131

    Article  CAS  PubMed  Google Scholar 

  18. Ogata D, Tsuchida T (2019) Systemic immunotherapy for advanced cutaneous squamous cell carcinoma. Curr Treat Options in Oncol 20(4):30. https://doi.org/10.1007/s11864-019-0629-2

    Article  Google Scholar 

  19. Paoli J, Gyllencreutz JD, Fougelberg J, Backman EJ, Modin M, Polesie S, Zaar O (2019) Nonsurgical options for the treatment of basal cell carcinoma. Dermatol Pract Concept 9(2):75–81. https://doi.org/10.5826/dpc.0902a01

    Article  PubMed  PubMed Central  Google Scholar 

  20. Preneau S, Rio E, Brocard A, Peuvrel L, Nguyen J‑M, Quéreux G, Dreno B (2014) Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat 25(5):424–427. https://doi.org/10.3109/09546634.2012.751481

    Article  CAS  PubMed  Google Scholar 

  21. Stoscheck CM, King LE (1986) Role of epidermal growth factor in carcinogenesis. Cancer Res 46(3):1030–1037

    CAS  PubMed  Google Scholar 

  22. Svendsen FH, Heegaard S (2017) Lymphoma of the eyelid. Surv Ophthalmol 62(3):312–331. https://doi.org/10.1016/j.survophthal.2016.11.009

    Article  PubMed  Google Scholar 

  23. Tchanque-Fossuo CN, Eisen DB (2018) A systematic review on the use of cryotherapy versus other treatments for basal cell carcinoma. Dermatol Online J 24(11):3

    Google Scholar 

  24. Weiling M, Bergua A, Kruse FE, Holbach L (2016) Therapie bei malignen Lidtumoren. Ophthalmologe 113(12):1095–1108. https://doi.org/10.1007/s00347-016-0387-5

    Article  CAS  PubMed  Google Scholar 

  25. Wittels W (1964) Experiences and indications for therapy with liquid nitrogen. Arch Klin Exp Dermatol 219:693–696

    Article  CAS  Google Scholar 

  26. Wong S‑F (2005) Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 27(6):684–694. https://doi.org/10.1016/j.clinthera.2005.06.003

    Article  CAS  PubMed  Google Scholar 

  27. Wong KY, Fife K, Lear JT, Price RD, Durrani AJ (2017) Vismodegib for locally advanced periocular and orbital basal cell carcinoma: a review of 15 consecutive cases. Plast Reconstr Surg Glob Open 5(7):e1424. https://doi.org/10.1097/GOX.0000000000001424

    Article  PubMed  PubMed Central  Google Scholar 

  28. Yin VT, Pfeiffer ML, Esmaeli B (2013) Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma. Ophthal Plast Reconstr Surg 29(2):87–92. https://doi.org/10.1097/IOP.0b013e3182831bf3

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C. Girbardt FEBO.

Ethics declarations

Interessenkonflikt

C. Girbardt, A. Mößner, P. Wiedemann und S. Grunewald geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Für Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, über die Patienten zu identifizieren sind, liegt von ihnen und/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Girbardt, C., Mößner, A., Wiedemann, P. et al. Therapiealternativen zur chirurgischen Versorgung maligner Lidtumoren und deren Vorläuferstufen. Ophthalmologe 117, 478–483 (2020). https://doi.org/10.1007/s00347-020-01072-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-020-01072-y

Schlüsselwörter

Keywords

Navigation